Among the top ranked predicted hits, 27 commercially available molecules were acquired and firstly tested for their capability to affect the intracellular localization of CtBP1/BARS in the human A375MM melanoma cell line (a cancer type in which the CtBP1/BARS expression levels are more pronounced than in other tumors; Supplementary Fig. 1A) by immunofluorescence microscopy. Here, CTBP1 is linked to melanoma.